In order to determine whether the immediate inclusion of anti-retroviral pre-exposure prophylaxis (PrEP) as part of the HIV risk reduction package for men who have sex with men who are at risk of acquiring HIV is clinically effective and cost-effective, a large trial of ~5,000 MSM would need to be conducted. The purpose of the PROUD pilot is to determine the feasibility of conducting such a trial in the UK.